Omnitrix
Real-time health monitoring at scale
Introduction
Imagine a wearable device that can continuously monitor the concentrations of specific molecules in your body (say metabolic markers such as insulin or cortisol, or reproductive hormones such as LH, FSH or even prescription drugs such as opioids), and relay the data to your healthcare provider who can precisely tune the therapy or drug dosage to meet your specific individual needs. No more misdiagnoses, drug overdosage, underdosage, ineffective treatments or recurrent hospital visits for repeated blood draws. At Omnitrix, we are developing the technology to continuously monitor proteins, small molecules, and metabolites to enable personalized healthcare through real-time and at-scale molecular sensing. Our mission is to tap into the power of real-time multi-analyte monitoring to enable truly personalized healthcare.
Problem
Traditional paradigms of clinical diagnostics and therapy are not personalized to an individual's specific needs or their health changes over time. These approaches often depend on population-based physical indicators such as age, weight, or body mass index, which frequently do not accurately reflect the physiological condition at an individual level, or indirect parameters such as genetics, which are poor predictors of a patient’s current state of health and effectiveness of therapeutic dosing. Proteins and metabolites, which are constantly changing in our bodies at the molecular level are linked to the health of organs and regulatory mechanisms. Characterizing these molecules over time will enable accurate prediction and precise treatment of an individual's condition. Despite the large market size of these biomolecules (approximately $90 billion for proteins and $60 billion for metabolites), there is currently no technology available that can continuously monitor a variety of these molecules in real-time.
The Continuous Glucose Monitor (CGM) segment for patient-specific health management in Type 1 diabetes is currently the only market that has tapped into constant monitoring of a molecule. Even the success of CGMs (with a market size of approximately $8 billion) is not due to their ability to monitor the protein insulin over time, but instead the ability to predict the proxy of insulin levels based on the sensed glucose levels using a redox-based sensor that can quantify glucose. Currently, there are no FDA-approved wearable technologies that can sense and monitor multiple clinically significant and non-redox-active biomolecules such as proteins and metabolites, and therapeutics.
Opportunity
We are developing an Electromoriogram, an extremely modular and wearable bioelectronic device that uses affinity interactions to continuously monitor desired biomolecules of interest in the interstitial fluid over time, thereby vastly expanding the scope of molecules that can be sensed. Our technology will enable clinicians to use real-time data and analytics to make diagnoses, tailor the treatment and/or dosage of treatment to an individual, and evaluate its effectiveness over time. The technology can open up new markets in personalized healthcare such as women's health monitoring, metabolic health monitoring, vital health monitoring in intensive care units, cardiovascular and renal health monitoring, among many others.